Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» momelotinib
momelotinib
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision
GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision
Fierce Biotech
GSK
Sierra Oncology
momelotinib
myelofibrosis
ASH 2022
Flag link:
Was This Acquisition a Smart Move for GlaxoSmithKline?
Was This Acquisition a Smart Move for GlaxoSmithKline?
Motley Fool
GSK
Sierra Oncology
momelotinib
bone marrow cancer
M&A
Flag link:
Sierra doubles down on ex-Gilead drug, deprioritizes other assets
Sierra doubles down on ex-Gilead drug, deprioritizes other assets
Fierce Biotech
Sierra Oncology
myelofibrosis
Gilead Sciences
momelotinib
Flag link:
Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug
Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug
Xconomy
Gilead Sciences
Sierrra Oncology
myelofibrosis
momelotinib
Flag link:
Gilead Fails to Beat Incyte’s Jakafi Drug
Gilead Fails to Beat Incyte’s Jakafi Drug
Investopedia
Gilead Sciences
Jakafi
Incyte
momelotinib
myelofibrosis
Flag link: